BeiGene, Singlomics sign licencing agreement on neutralising Covid-19 antibodies

BeiGene, Singlomics sign licencing agreement on neutralising Covid-19 antibodies

Source: 
Pharmaceutical Business Review
snippet: 

BeiGene has entered into an exclusive licence agreement with Singlomics (Beijing DanXu) Biopharmaceuticals for neutralising Covid-19 antibodies.